Testicular Germ Cell Tumor
Conditions
Keywords
stage II malignant testicular germ cell tumor, stage III malignant testicular germ cell tumor
Brief summary
RATIONALE: Learning about long-term effects in patients with testicular cancer may help doctors plan better treatment and follow-up care. PURPOSE: This clinical trial is using CT scans to follow patients who have been treated for metastatic testicular cancer.
Detailed description
OBJECTIVES: * To assess the frequency of relapse or recurrent abnormalities detected by CT scan in patients on long-term follow-up for metastatic nonseminomatous germ cell tumour (NSGCT). * To assess the utility of CT scan-assessment in these patients. * To assess the prognostic factors predictive of late relapse in NSGCT. OUTLINE: This is a multicenter study. Patients are screened by CT scan of the chest, abdomen, and pelvis for detectable abnormalities or indications of late relapse. Scans are classified as positive or negative, according to standard CT criteria, by a radiologist with expertise in testicular cancer imaging. Patients with negative scans are followed yearly by clinical examination and tumor marker assessment, and every 5 years by CT imaging. Additional follow-up is performed at the discretion of the attending physician. Patients with positive scans undergo confirmation of relapse, whenever possible, by surgical excision or biopsy and treatment is initiated according to best clinical practice. If the follow-up scan is equivocal, patients are advised to have a follow-up scan of the affected region in 6 months.
Interventions
OTHERbiomarker analysis
PROCEDUREcomputed tomography
Sponsors
Royal Marsden NHS Foundation Trust
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
DISEASE CHARACTERISTICS: * Diagnosis of metastatic nonseminomatous germ cell tumor (NSGCT) at risk of developing late relapse of residual abnormality * Royal Marsden Hospital stage II-IV disease * Treatment for NSGCT completed within the past 5 to10 years * No evidence of disease after completion of chemotherapy, as demonstrated by negative CT scans within the past 3 years PATIENT CHARACTERISTICS: * Willing to attend follow-up for five years * No contraindication to CT imaging PRIOR CONCURRENT THERAPY: * See Disease Characteristics
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rate of abnormalities due to nonseminomatous germ cell tumour (NSGCT) detected on initial CT-scan | — |
Secondary
| Measure | Time frame |
|---|---|
| Rate of false positive abnormalities not due to NSGCT but due to benign process | — |
| Rate of relapse following initial CT scan | — |
| Number of abnormalities detected on second CT scan | — |
Countries
United Kingdom
Outcome results
None listed